Navigation Links
FDA to Review Potential New Use of XGEVA® (Denosumab) at Oncologic Drugs Advisory Committee Meeting
Date:12/29/2011

ussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)

[i] Tannock IF, Wit R, Berry WR, Horti J, Pluzanska A, Chi K, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-12.

[ii] Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-1520.

[iii] Prostate cancer clinical trial end points: ''RECIST''ing a step backwards. American Association for Cancer Research website. clincancerres.aacrjournals.org. Accessed on February 16, 2011.

[iv] Coleman RE. Skeletal complications of malignancy. Cancer. 1997; 80(suppl): 1588-1594.

[v] Lipton A, Theriault RL, Hortobagyi GN. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer. 2000;88:1082-1090.

[vi] Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlated with reduced survival in patients with malignant bone disease. Cancer. 2007;110:1860-1867.

[vii] Rosen LS, Gordon D, T
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity
2. Bipartisan Group of 22 House Members ask CMS to Stop Prepayment Review Project that would Jeopardize Care for Medicare Beneficiaries
3. Anthera Announces Completion of Safety Review by DSMB for VISTA-16
4. Homecare Providers and Consumer Advocates Urge Congress to Stop Ineffective Medicare Payment Review Process for Mobility Equipment
5. M&A Surges, Companion Diagnostics Accelerate, and Early Detection Offers New Prospects, Finds PwCs Biennial Review of the In Vitro Diagnostics Industry
6. Physicians Capital Investments Announces Pedro Vergne-Marini, MD Named to Beckers ASC Review "350 People in the ASC Industry to Know"
7. Avreo Previews Version 7 RIS/PACS at RSNA
8. Futuremed and Cardinal Health Canada Inc. Report on Developments in Competition Bureau Review of the Proposed Acquisition
9. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
10. U.S. Food and Drug Administration (FDA) Delays Review of Takedas Investigational Type 2 Diabetes Therapies, Alogliptin and Alogliptin/Pioglitazone
11. Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Pa. , July 10, 2014 ... Moberg Research,s (Moberg) medical device manufacturing facility. Rep. ... Moberg,s advanced neurological monitors facilitate cutting-edge research in ... Rep. Kennedy and mental health advocate, Garen ... organization dedicated to fostering fundamental changes that will ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
(Date:7/10/2014)... July 10, 2014 CVS Caremark Corporation (NYSE: ... has approved a quarterly dividend of $0.275 (27.5 cents) per ... on August 1, 2014, to holders of record on July ... CVS Caremark is dedicated to helping people on their path ... the United States . Through the company,s ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Among High-Risk Infants Versus,Current Standard of Care ... Related Lower Respiratory Infections -, TORONTO, May ... positive results from a large prospective trial,conducted ... The,trial compared motavizumab, the investigational monoclonal antibody,(MAb) ...
... Presentation for Pristiq Occurs at the 55th ... Obstetricians and,Gynecologists, COLLEGEVILLE, Pa., May 09, 2007 ... , presented results from the,first Phase 3 ... moderate-to-severe vasomotor symptoms (hot flashes,and night sweats) ...
Cached Medicine Technology:MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 2MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 3MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 4MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 5MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 6MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 7Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 2Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 3Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 4Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 5Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 6
(Date:7/12/2014)... Using and carrying around a catheter ... from Ashland, Va., decided that there needed to be ... to conceive of our design," he said. , They ... which provides an inconspicuous way to use and carry ... as promotes comfort and peace of mind. Producible in ...
(Date:7/12/2014)... July 12, 2014 “Critical Care ... New and Late-Stage Four-Factor PCCs and Recombinant Products ... the critical care market in the US, UK, ... report provides an estimation of market size for ... covers critical care indications that are being treated ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 A recent article ... provides a trio of suggestions for those seeking cosmetic ... days are rapidly approaching and the heat begins to enliven ... to their summer clothing, realizing that they didn’t work out ... , This can cause a sudden surge of people eager ...
(Date:7/12/2014)... Maxim Peptide, a website that features ... solely in scientific experiments, is currently celebrating its second ... Maxim Peptide, which was created by the founders of ... updated website that now features a special deals section. ... with fascinating articles about peptide research, including a new ...
(Date:7/11/2014)... July 11, 2014 The American Association ... 55 poison centers are commending Senator Bill Nelson (D-FL) ... Act of 2014 on July 10, 2014. Along with ... Products Safety Commission (CPSC) to enact rules requiring safer, ... , Senate co-sponsors of the bill include: ...
Breaking Medicine News(10 mins):Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3
... Blue Plan Experienced a 15 Percent Increase ... a New Report from HealthLeaders-InterStudy, NASHVILLE, ... of managed care market intelligence, reports that ... medication use,through pharmacy programs and public education ...
... Health,Care Systems, Inc. (HCS), a leading provider ... medication reconciliation solutions, has entered,into an agreement with ... not-for-profit hospitals in the nation with 881 licensed,acute ... facility for The,University of Alabama at Birmingham,s Family ...
... treatment could help 3.3 million U.S. sufferers, ... Medical, Inc. today,announced that 98.4 percent of ... called Barrett,s esophagus were free of the ... the HALO ablation,system. The results were published ...
... release of milk in humans, animals , , FRIDAY, July 18 ... speaking? , Researchers have discovered that babies nursing at ... to release of oxytocin, known as the "trust" hormone in ... to be involved in trust and love in both humans ...
... restored brain,s ability to make new cells , , FRIDAY, July ... day may lead to health issues, including depression, a new ... a causal link between abstinence from alcohol drinking and depression," ... and pharmacology in the University of North Carolina School of ...
... in French . , Winnipeg (July ... Canadian Institutes of Health Research (CIHR) was announced today ... Secretary for Health, on behalf of Tony Clement, Minister ... investigating how to improve the application of mental health ...
Cached Medicine News:Health News:New York's Excellus BlueCross BlueShield to Continue Generic Medication Promotion to Help Control Costs 2Health News:Huntsville Hospital Signs With Health Care Systems, Inc. for Automated Medication Reconciliation Services 2Health News:Precancerous Esophagus Disease Eliminated in 98.4% of Patients Treated With HALO Ablation System 2Health News:Precancerous Esophagus Disease Eliminated in 98.4% of Patients Treated With HALO Ablation System 3Health News:Suckling Infant Triggers 'Trust' Hormone in Moms 2Health News:Research Finds Causal Link Between Ending Drinking, Depression 2Health News:CIHR announces $4.4 million to improve mental health of Canadians 2
This a new dedicated VICTOR2 model for fluorescence, fluorescence polarization and luminescence measurement with stacker and robotic loading....
This a new dedicated VICTOR2 model for fluorescence and luminescence detection with stacker and robotic loading....
This is the modular manually operated VICTOR2 multilabel counter, with the addition of a xenon flash lamp for time-resolved fluorescence counting. Along with this option comes flash absorbance and du...
... multimode readers offering 96-channel parallel detection of ... and 1,536-well microtiter plates. Compact workstations ... for the transport of microtiter plates with ... day. The need for mechanical switching required ...
Medicine Products: